

Clinical Trial Protocol

Iranian Registry of Clinical Trials

02 Jul 2026

Comparative efficacy assessment of Tamsulosin vs. Tamsulosin plus Pentoxifylline in the treatment of LUTS/BPH in two 30 persons groups of patients: A preliminary study

Protocol summary

Study aim

To determine and compare the efficacy assessment of Tamsulosin plus Pentoxifylline Vs Tamsulosin in the treatment of Lower urinary tract symptoms (LUTS) of Benign prostate hyperplasia(BPH)

Design

The clinical trial has a control group and a parallel group that is double-blinded. The total volume of the study is 60 people who are divided randomly into two groups of 30 people.

Settings and conduct

This study was conducted in Shahid Motahari Clinic in Shiraz and the patients and the person who delivers the drugs to patients have been blinded and do not know whether pentoxifylline is prescribed or Placebo. At the beginning of the work, the patient will be taken a complete history and the amount of blood pressure, creatinine, PSA and prostate volume will be evaluated and if he had the necessary conditions about the existing study and the possibility of participating in it for the patient, and if the patient's consent after obtaining written consent from him, he would be entered and the necessary variables will be evaluated before the beginning of treatment and 12 weeks after the start of treatment.

Participants/Inclusion and exclusion criteria

Inclusion criteria: Age>40, Prostate volume>20ml, creatinine<2, maximum urinary flow rate<15ml/s, Voide volume>100ml, International Prostate Symptom Score>13 Exclusion criteria: Age<40, Previous prostate surgery, History of prostate cancer, Renal dysfunction, History of severe liver impairment, Severe cardiovascular diseases, Active Urinary tract infection, Bladder calculus, Exposure to sex hormone within 3 months prior, History of neurogenic bladder, History of urethral stricture, Severe hypotension, Postvoid residual urine volume of > 250 ml

Intervention groups

Administration of pentoxifylline and tamsulosin in men with Lower urinary tract symptoms (LUTS) of Benign prostate hyperplasia(BPH)

Main outcome variables

International Prostate Symptom Score Quality of Life
Maximum urinary flow rate Voided volume

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20210729052012N1**

Registration date: **2022-01-20, 1400/10/30**

Registration timing: **prospective**

Last update: **2022-01-20, 1400/10/30**

Update count: **0**

Registration date

2022-01-20, 1400/10/30

Registrant information

Name

Alireza Dehghanmanshadi

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 71 3820 6907

Email address

alireza.dehghan68@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2022-02-04, 1400/11/15

Expected recruitment end date

2022-06-05, 1401/03/15

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Comparative efficacy assessment of Tamsulosin vs. Tamsulosin plus Pentoxifylline in the treatment of LUTS/BPH in two 30 persons groups of patients: A preliminary study

Public title

Comparative efficacy assessment of Tamsulosin vs. Tamsulosin plus Pentoxifylline in the treatment of LUTS/BPH: A preliminary study

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

Age>40 International Prostate Symptom Score(IPSS)>13
Prostate Volume>20ml maximum urinary flow rate(Qmax)<15ml/s Voided Volume>100ml creatinine(Cr)<2

Exclusion criteria:

Age<40 history of prostate cancer renal dysfunction previous prostate surgery bladder calculus active UTI postvoid residual urine volume of > 250 mL exposure to sex hormone within 3 months prior history of severe liver impairment history of severe cardiovascular diseases severe hypotension history of neurogenic bladder history of urethral stricture

Age

From **40 years** old

Gender

Male

Phase

4

Groups that have been masked

- Participant
- Care provider

Sample size

Target sample size: **60**

Randomization (investigator's opinion)

Randomized

Randomization description

Eligible patients after first visit, will be divide in two groups with randomizer by third party

Blinding (investigator's opinion)

Double blinded

Blinding description

Blinding is done so that in the group receiving Pentoxifylline, this pill is powdered and poured into the capsules and delivered to the patients and in the group that should only receive Tamsulosin, In addition to Tamsulosin, placebo is given. Placebo so that starch is poured into the capsules and packed and delivered to the patients And finally, the patient doesn't know if he's

using pentoxifylline or placebo.

Placebo

Used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics Committee of Shiraz University of Medical Sciences

Street address

University of Medical Sciences building, near Helal Ahmar, Zand street

City

Shiraz

Province

Fars

Postal code

7134814336

Approval date

2020-08-03, 1399/05/13

Ethics committee reference number

IR.SUMS.MED.REC.1399.261

Health conditions studied**1****Description of health condition studied**

Benign Prostate Hyperplasia

ICD-10 code

N40.1

ICD-10 code description

Enlarged prostate with lower urinary tract symptoms

Primary outcomes**1****Description**

International Prostate Symptom Score

Timepoint

At the beginning of the study and 12 weeks after treatment

Method of measurement

International Prostate Symptom Score chart

2**Description**

Quality of Life

Timepoint

At the beginning of the study and 12 weeks after

treatment

Method of measurement

Quality of life due to urinary symptoms chart

3**Description**

Maximum urinary flow rate

Timepoint

At the beginning of the study and 12 weeks after treatment

Method of measurement

Uroflowmetry

4**Description**

Voided volume

Timepoint

At the beginning of the study and 12 weeks after treatment

Method of measurement

Uroflowmetry

Secondary outcomes

empty

Intervention groups**1****Description**

Intervention group: Tamsulosin 0.4mg everyday and Pentoxifylline 400mg every 8 hour in 12 weeks were given.

Category

Treatment - Drugs

2**Description**

Control group: Tamsulosin 0.4mg everyday and placebo every 8 hour in 12 weeks were given.

Category

Treatment - Drugs

Recruitment centers**1****Recruitment center****Name of recruitment center**

Shahid Motahari Clinic

Full name of responsible person

Soroush Sadr

Street address

Shahid Motahari Clinic, Namazi Sq

City

Shiraz

Province

Fars

Postal code

7193613111

Phone

+98 71 3612 1000

Email

sadr.soroush@gmail.com

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Shiraz University of Medical Sciences

Full name of responsible person

Mehdi Shirazi

Street address

University of Medical Sciences building, near Helal Ahmar, Zand street

City

Shiraz

Province

Fars

Postal code

7134814336

Phone

+98 71 3230 5410

Email

shirazim@sums.ac.ir

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Shiraz University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

Academic

Person responsible for general inquiries**Contact****Name of organization / entity**

Shiraz University of Medical Sciences

Full name of responsible person

Alireza Dehghanmanshadi

Position

Resident

Latest degree

Medical doctor

Other areas of specialty/work

Urology

Street address

No 41, Minor 5/3, Alley 5, Bagh Hows street, Zerehi

Blv
City
Shiraz
Province
Fars
Postal code
7175956585
Phone
+98 71 3820 6907
Email
alireza.dehghan68@gmail.com

Person responsible for scientific inquiries

Contact

Name of organization / entity
Shiraz University of Medical Sciences
Full name of responsible person
Mehdi Shirazi
Position
Professor
Latest degree
Subspecialist
Other areas of specialty/work
Urology
Street address
Namazi hospital, Zand street
City
Shiraz
Province
Fars
Postal code
7193613311
Phone
+98 71 3647 4332
Email
shirazim@sums.ac.ir

Person responsible for updating data

Contact

Name of organization / entity
Shiraz University of Medical Sciences
Full name of responsible person
Alireza Dehghanmanshadi
Position
Resident
Latest degree
Medical doctor
Other areas of specialty/work

Urology
Street address
No 41, Minor 5/3, Alley 5, Bagh Hows street, Zerehi
Blv
City
Shiraz
Province
Fars
Postal code
7175956585
Phone
+98 71 3820 6907
Email
alireza.dehghan68@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Yes - There is a plan to make this available

Data Dictionary

Yes - There is a plan to make this available

Title and more details about the data/document

Study Statistical Data- The entire data of individuals can be shared after people are identifiable.

When the data will become available and for how long

Start accessing 6 months after the results are printed

To whom data/document is available

Researchers working in academic and scientific institutions

Under which criteria data/document could be used

Certain conditions are not required.

From where data/document is obtainable

Alireza Dehghanmanshadi Email:
alireza.dehghan68@gmail.com

What processes are involved for a request to access data/document

The applicant sends his request via email and after reviewing the request and confirming it, the documents will be obtained within about a month.

Comments